Nxera Reports Positive Phase 3 Results for Daridorexant
TOKYO, Japan and CAMBRIDGE, United Kingdom | January 19, 2026 — Nxera Pharma Co., Ltd. announced positive top-line results...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
TOKYO, Japan and CAMBRIDGE, United Kingdom | January 19, 2026 — Nxera Pharma Co., Ltd. announced positive top-line results...
